Long-acting Beta2-agonists (LABA) in Chronic Obstructive Pulmonary Disease: Efficacy and Safety

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2009 Mar 14

PMID 19281071

Citations 17

Authors

Andrea Rossi

Sonia Khirani

Mario Cazzola

Affiliations

Soon will be listed here.

Abstract

COPD is characterized by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy. The management of patients with COPD has taken a totally new direction over the past 20 years, thank to the use of novel therapies aimed to improve and modify the natural history of COPD. Long-acting bronchodilators, including long-acting beta2-agonists (LABAs), were introduced several years ago in order to enhance improvements in lung function, health status related quality of life, and reduce the rate of exacerbations. These effects can be boosted by the combination of LABAs with long-acting anticholinergic, and/or with inhaled corticosteroids. Inhaled LABAs are commonly well tolerated although adverse effects such as tremor and palpitations are occasionally troublesome.

Citing Articles

The Effect of Inhaled Beta-2 Agonists on Heart Rate in Patients With Asthma: Sensor-Based Observational Study.

Khusial R, Sont J, Usmani O, Bonini M, Chung K, Fowler S JMIR Cardio. 2024; 8:e56848.

PMID: 39661964 PMC: 11669870. DOI: 10.2196/56848.

Challenges and Opportunities in COPD Management in Latin America: A Review of Inhalation Therapies and Advanced Drug Delivery Systems.

Izquierdo-Condoy J, Salazar-Santoliva C, Salazar-Duque D, Palacio-Davila Y, Hernandez-Londono J, Orozco-Gonzalez R Pharmaceutics. 2024; 16(10).

PMID: 39458647 PMC: 11510842. DOI: 10.3390/pharmaceutics16101318.

Lung Hyperinflation as Treatable Trait in Chronic Obstructive Pulmonary Disease: A Narrative Review.

Koopman M, Posthuma R, Vanfleteren L, Simons S, Franssen F Int J Chron Obstruct Pulmon Dis. 2024; 19:1561-1578.

PMID: 38974815 PMC: 11227310. DOI: 10.2147/COPD.S458324.

Jarab A, Al-Qerem W, Alzoubi K, Abu Heshmeh S, Mukattash T, Naser A PLoS One. 2023; 18(10):e0293342.

PMID: 37883370 PMC: 10602230. DOI: 10.1371/journal.pone.0293342.

The Complex Association between COPD and COVID-19.

Awatade N, Wark P, Chan A, Al Mamun S, Mohd Esa N, Matsunaga K J Clin Med. 2023; 12(11).

PMID: 37297985 PMC: 10253799. DOI: 10.3390/jcm12113791.

References

Rossi A, Kristufek P, Levine B, Thomson M, Till D, Kottakis J . Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002; 121(4):1058-69. DOI: 10.1378/chest.121.4.1058. View

Salpeter S, Buckley N, Salpeter E . Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med. 2006; 21(10):1011-9. PMC: 1831628. DOI: 10.1111/j.1525-1497.2006.00507.x. View

Anthonisen N, Skeans M, Wise R, Manfreda J, Kanner R, Connett J . The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005; 142(4):233-9. DOI: 10.7326/0003-4819-142-4-200502150-00005. View

Matera M, Sanduzzi A, Ponticiello A, Vatrella A, Salzillo A, Cazzola M . An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses. Respiration. 2005; 72(5):466-70. DOI: 10.1159/000087669. View

Stewart A, Waterhouse J, Howard P . The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med. 1995; 89(2):79-84. DOI: 10.1016/0954-6111(95)90188-4. View

Hogg J . Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004; 364(9435):709-21. DOI: 10.1016/S0140-6736(04)16900-6. View

Salpeter S, Buckley N, Ormiston T, Salpeter E . Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006; 144(12):904-12. DOI: 10.7326/0003-4819-144-12-200606200-00126. View

Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

Rabe K . Treating COPD--the TORCH trial, P values, and the Dodo. N Engl J Med. 2007; 356(8):851-4. DOI: 10.1056/NEJMe068307. View

10.

Wagner P, Dantzker D, Iacovoni V, Tomlin W, West J . Ventilation-perfusion inequality in asymptomatic asthma. Am Rev Respir Dis. 1978; 118(3):511-24. DOI: 10.1164/arrd.1978.118.3.511. View

11.

Cazzola M, Noschese P, de Michele F, DAmato G, Matera M . Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. Respir Med. 2005; 100(2):212-7. DOI: 10.1016/j.rmed.2005.04.024. View

12.

ODonnell D, Revill S, WEBB K . Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164(5):770-7. DOI: 10.1164/ajrccm.164.5.2012122. View

13.

Ferguson G, Funck-Brentano C, Fischer T, Darken P, Reisner C . Cardiovascular safety of salmeterol in COPD. Chest. 2003; 123(6):1817-24. DOI: 10.1378/chest.123.6.1817. View

14.

Santus P, Centanni S, Morelli N, Di Marco F, Verga M, Cazzola M . Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists. Respir Med. 2007; 101(8):1798-803. DOI: 10.1016/j.rmed.2007.02.007. View

15.

Cooper C . The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006; 119(10 Suppl 1):21-31. DOI: 10.1016/j.amjmed.2006.08.004. View

16.

Qaseem A, Snow V, Shekelle P, Sherif K, Wilt T, Weinberger S . Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007; 147(9):633-8. View

17.

Siafakas N, Vermeire P, Pride N, Paoletti P, Gibson J, Howard P . Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995; 8(8):1398-420. DOI: 10.1183/09031936.95.08081398. View

18.

Rogers D . Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther. 2004; 18(1):1-8. DOI: 10.1016/j.pupt.2004.08.001. View

19.

Zimmer G, Dahinten A, Fitzner A, Halbig S, Noll T, Treusch F . beta-agonistic bronchodilators: comparison of dose/response in working rat hearts. Chest. 2000; 117(2):519-29. DOI: 10.1378/chest.117.2.519. View

20.

Sutherland E, Cherniack R . Management of chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(26):2689-97. DOI: 10.1056/NEJMra030415. View